Do Corporate Alliances Affect Biotechs' Market Performance?
Executive Summary
Is there a positive correlation between the number of corporate alliances biotechs have signed and their success at maintaining, or growing, their market valuations since their IPOs? To find out, we took the forty largest biotech IPOs completed in 1996 and 1997 and plotted their recent market valuations and percentage gain or loss over their IPO valuations against the number of significant corporate outlicensings they had signed since IPO.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.